EGFR and non-small cell lung carcinoma: NSCLC patients harbor the two front-line sensitizing EGFR mutations (L858R in exon 21 and deletions in exon 19), rendering them susceptible to treatment by EGFR tyrosine kinase inhibitors (EGFR-TKIs) [2].